The Combined EGFR Protein Expression Analysis Refines the Prognostic Value of the MGMT Promoter Methylation Status in Glioblastoma

Glioblastoma (GB) incidence is about 2-3 cases per 100,000 people [1], and its prognosis is extremely poor with a median survival time of only 14.5 months from diagnosis in clinical trials [2] with 3-year survival rates rarely reaching 5% [3]. However, in clinical practice, a great variability in terms of prognosis exists in unselected patients. Extensive characterisation by multiple omic platforms is improving our knowledge of the molecular bases underlying the nature of GB aggressiveness [4,5].

Source: Clinical Neurology and Neurosurgery - July 17, 2016 Category: Neurosurgery Authors: Paolo Tini, Pierpaolo Pastina, Valerio Nardone, Lucio Sebaste, Marzia Toscano, Clelia Miracco, Alfonso Cerase, Luigi Pirtoli Source Type: research